Share Email Print
cover

Proceedings Paper

The use of upconverting phosphors in point-of-care (POC) testing
Author(s): Hans J. Tanke; Michel Zuiderwijk; Karien C. Wiesmeijer; Robert N. Breedveld; William R. Abrams; Claudia J. de Dood; Elisa M. Tjon Kon Fat; Paul L. A. M. Corstjens
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Point-of-care (POC) testing is increasingly applied as a cost effective alternative to many diagnostic tests. Key in POC testing is to create sufficient assay sensitivity with relatively low cost reagents and equipment. For this purpose we have employed a unique reporter, upconverting phosphor (UCP) particles, in combination with lateral flow (LF) assays. UCPs, submicron ceramic particles doped with rare earth ions (lanthanides), convert infrared to visible light and do not suffer from autofluorescence which limits conventional fluorescence based assays. Low cost handheld readers and microfluidics were evaluated in various applications. Designed assays are well suited for applications outside diagnostic laboratories, in resource poor settings, and can even be used by patients at home. Using two distinctly different UCP-LF assay formats, we focussed on assays for infectious diseases based on the detection of pathogen-specific antibodies and/or antigens including nucleic acids to demonstrate active infection with HIV. Only minor adaptation of the standard UCP-LF assay format is needed to render the format suitable for applications involving low affinity capture antibodies (e.g. in the detection of neurotoxin, botulism), capture of small molecules (e.g. detection of melatonin, a key hormone in chronopharmacology) or the use of dry UCP reagents (e.g. detection of protein based fruit-ripening markers, of economic interest in agriculture). Finally, we anticipate on developments in healthcare (personalized medicine) by discussing the potential of one of the UCP-LF assay formats to measure serum trough levels of immunodrugs (e.g. infliximab or adalimumab) in patients treated for inflammatory bowel disease and rheumatoid arthritis.

Paper Details

Date Published: 4 March 2014
PDF: 15 pages
Proc. SPIE 8947, Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XII, 89470P (4 March 2014); doi: 10.1117/12.2036906
Show Author Affiliations
Hans J. Tanke, Leiden Univ. Medical Ctr. (Netherlands)
Michel Zuiderwijk, Leiden Univ. Medical Ctr. (Netherlands)
Karien C. Wiesmeijer, Leiden Univ. Medical Ctr. (Netherlands)
Robert N. Breedveld, Leiden Univ. Medical Ctr. (Netherlands)
William R. Abrams, New York Univ. College of Dentistry (United States)
Claudia J. de Dood, Leiden Univ. Medical Ctr. (Netherlands)
Elisa M. Tjon Kon Fat, Leiden Univ. Medical Ctr. (Netherlands)
Paul L. A. M. Corstjens, Leiden Univ. Medical Ctr. (Netherlands)


Published in SPIE Proceedings Vol. 8947:
Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XII
Daniel L. Farkas; Dan V. Nicolau; Robert C. Leif, Editor(s)

© SPIE. Terms of Use
Back to Top